LOS ANGELES, Calif. — Salt AI, a provider of contextual artificial intelligence for life sciences and health technology applications, announced the addition of four senior executives to its leadership team. The appointments follow the company’s recent $10 million funding round and reflect Salt AI’s momentum as it scales its adaptive SaaS pipeline for translational science and drug development.
The expanded leadership group brings extensive experience across biotechnology, artificial intelligence, data engineering, and commercialization, supporting the company’s mission to help life science organizations accelerate discovery and development using adaptive AI systems.
Nate Beyor, PhD, has joined Salt AI as Chief Business Officer. Previously the global leader of Health Tech at Boston Consulting Group, Beyor brings more than two decades of experience advising and scaling companies across biotech, medtech, and healthcare. He will oversee corporate strategy, the company’s solutions portfolio, and market expansion efforts.
Bob Battista, Founder of Doctor Evidence and a longtime expert in medical intelligence platforms, has been appointed Head of Commercial. He will lead Salt AI’s commercialization strategy and its partnerships across healthcare and life sciences.
Toby Sayre, formerly with Concert AI, has joined as Vice President of Sales. His experience in life sciences consulting, business development, and AI-driven solutions will support Salt AI’s expansion in biotech and pharmaceutical markets.
Dan Sheikh, most recently with Thermo Fisher Scientific, has been named Vice President of AI Solutions. A seasoned data engineer and machine learning specialist, he will lead the technical arm of Salt AI’s customer-facing team and help guide deployment of the company’s AI solutions.
“Delivering real AI value in life sciences depends on pairing a world-class technology backbone with a deep understanding of the science itself,” said Aber Whitcomb, CEO and Co-Founder of Salt AI. “At Salt AI, we’re building that bridge intentionally — assembling a team that excels at both. With this new wave of industry-leading talent and fresh funding, we’re expanding our capacity to help organizations achieve breakthroughs that simply weren’t possible before.”
The company’s leadership expansion follows growing demand for AI-enabled bioscience tools that combine advanced machine learning with modern data infrastructure to support real-world impact across the life sciences sector.
